Skip to main content

Advertisement

Log in

Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

In melanoma patients, CD8+ cytotoxic T cells have been found recognizing self-proteins of which the expression is restricted to the melanocytic lineage. These melanocyte differentiation antigens are expressed in normal melanocytes as well as in 80–100% of primary and metastatic melanoma. In this report, six HLA-A*0201–subtyped metastatic melanoma patients vaccinated with dendritic cells (DCs) pulsed with autologous tumor lysates and keyhole limpet hemocyanin (KLH) were screened for the presence of CD8+ T cells specific for three HLA-A*0201–binding peptides derived from the melanosomal antigens MART-1/Melan-A, gp100, and tyrosinase. For this purpose, nonstimulated as well as in vitro peptide-stimulated peripheral blood mononuclear cells (PBMCs) were tested for peptide-specific IFN-γ release by enzyme-linked immunosorbent spot (ELISpot) assays. Furthermore, expression of the melanosomal antigens MART-1/Melan-A, gp100, and tyrosinase in tumor lesions was analyzed by immunohistochemistry before and after vaccination. We also used the ELISpot technique to investigate whether KLH-specific T cells were induced and whether these cells released type 1 (IFN-γ) and/or type 2 (IL-13) cytokines. Our data show induction of CD8+ T cells specific for the melanosomal peptides MART-1/Melan-A27–35 or tyrosinase1–9, as well as IFN-γ–releasing KLH-specific T cells, in two of six vaccinated melanoma patients, but do not support an association between the induction of these T cells and clinical responses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Allen TM, Vogel TU, Fuller DH, Mothe BR, Steffen S, Boyson JE (2000) Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 164:4968

    CAS  PubMed  Google Scholar 

  2. Bakker AB, Schreurs MW, Tafazzul G, Boer AJd, Kawakami Y, Adema GJ, Figdor CG (1995) Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int J Cancer 62:97

    CAS  PubMed  Google Scholar 

  3. Bednarek MA, Sauma SY, Gammon MC, Porter G, Tamhankar S, Williamson AR, Zweerink HJ (1991) The minimum peptide epitope from the influenza virus matrix protein: extra and intracellular loading of HLA-A2. J Immunol 147:4047

    CAS  PubMed  Google Scholar 

  4. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478

    CAS  PubMed  Google Scholar 

  5. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y et al (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63:375

    CAS  PubMed  Google Scholar 

  6. Burg SHvd, Menon AG, Redeker A, Bonnet M-C, Drijhout JW, Tollenaar RAEM, Velde CJ, Moingeon P, Kuppen PJ, Offringa R, Melief CJ (2002) Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res 8:1019

    PubMed  Google Scholar 

  7. Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL (1998) Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother 21:27

    CAS  PubMed  Google Scholar 

  8. Coulie PG, Brichard V, Pel Av, Wolfel T, Schneider J, Traversari C, Mattei S, Plaen ED, Lurquin C, Szikora JP et al (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180:35

    CAS  PubMed  Google Scholar 

  9. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233

    CAS  PubMed  Google Scholar 

  10. Gilliet M, Kleinhans M, Lantelme F, Schadendorf D, Burg G, Nestle FO (2003) Intranodal injection of semimature monocyte-derived cells induces T helper type I responses to protein neoantigen. Blood 102:36

    Article  CAS  PubMed  Google Scholar 

  11. Griffioen M, Borghi M, Schrier PI, Osanto S (2001) Detection and Quantification of CD8+ T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-γ ELISPOT assay. Int J Cancer 93:549

    Article  CAS  PubMed  Google Scholar 

  12. Herr W, Linn B, Leister N, Wandel E, Meyer-zum BK, Wolfel T (1997) The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J Immunol Methods 203:141

    Article  CAS  PubMed  Google Scholar 

  13. Hilkens CM, Kalinski P, Boer Md, Kapsenberg ML (1997) Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 90:1920

    CAS  PubMed  Google Scholar 

  14. Jager E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D, Ilsemann C, Hagedorn M, Oesch F, Knuth A (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54

    PubMed  Google Scholar 

  15. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML (1999) T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20:561

    CAS  PubMed  Google Scholar 

  16. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347

    CAS  PubMed  Google Scholar 

  17. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelii N, Bourlond A, Vanwijck R, Hublet Y et al (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883

    CAS  PubMed  Google Scholar 

  18. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf S (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328

    CAS  PubMed  Google Scholar 

  19. Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA (1998) Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am U S A 4:316

    CAS  Google Scholar 

  20. Reynolds SR, Oratz R, Shapiro RL, Hao P, Yun Z, Fotino M, Vukmanovic S, Bystryn JC (1997) Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer 72:972

    Article  CAS  PubMed  Google Scholar 

  21. Ridge JP, Di-Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474

    CAS  PubMed  Google Scholar 

  22. Romero P, Cerottini JC, Waanders GA (1998) Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol Med Today 4:305

    CAS  PubMed  Google Scholar 

  23. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudkley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321

    CAS  PubMed  Google Scholar 

  24. Salgaller ML (1997) Monitoring of cancer patients undergoing active or passive immunotherapy. J Immunother 20:1

    CAS  PubMed  Google Scholar 

  25. Salter RD, Howell DN, Cresswell P (1985) Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21:235

    CAS  PubMed  Google Scholar 

  26. Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, Rammensee HG, Keilholz U (1997) A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 3:221

    CAS  PubMed  Google Scholar 

  27. Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V, Naeher H, Rammensee HG, Keilholz U (1997) Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer 71:932

    Article  CAS  PubMed  Google Scholar 

  28. Scheibenbogen C, Schmittel A, Keilholz U, Allgauer T, Hofmann U, Max R, Thiel E, Schadendorf D (2000) Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 23:275

    Article  CAS  PubMed  Google Scholar 

  29. Schmittel A, Keilholz U, Scheibenbogen C (1997) Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods 210:167

    Article  CAS  PubMed  Google Scholar 

  30. Schmittel A, Keilholz U, Max R, Thiel E, Scheibenbogen C (1999) Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma. Int J Cancer 80:39

    Article  CAS  PubMed  Google Scholar 

  31. Schmittel A, Keilholz U, Thiel E, Scheibenbogen C (2000) Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother 23:289

    Article  CAS  PubMed  Google Scholar 

  32. Schoenberger SP, Toes RE, Voort EIHvd (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480

    CAS  PubMed  Google Scholar 

  33. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, Driesch Pvd, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G (1999) Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T Cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669

    CAS  PubMed  Google Scholar 

  34. Wolfel T, Pel Av, Brichard V, Schneider J, Seliger B, Buschenfelde KHMz, Boon T (1994) Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24:759

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from the Dutch Cancer Society (NKB 95-1354).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dirk Schadendorf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Griffioen, M., Borghi, M., Schrier, P.I. et al. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. Cancer Immunol Immunother 53, 715–722 (2004). https://doi.org/10.1007/s00262-004-0514-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-004-0514-z

Keywords

Navigation